Press release
Investigation announced for Investors who lost money with shares of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL)

An investigation for investors in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) shares over potential securities laws violations.
Investors who purchased shares of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether certain statements by Zentalis Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
New York based Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
On June 18, 2024, Zentalis Pharmaceuticals, Inc. informed the market that "the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC)."
Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) declined from $27.51 per share on September 01, 2023, to as low as $2.83 per share on August 14, 2024.
Those who purchased shares of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) here
News-ID: 3627256 • Views: …
More Releases from Shareholders Foundation

Lawsuit filed for Investors who lost money with shares of Spirit Aviation Holdin …
An investor, who purchased shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ), filed a lawsuit over alleged violations of Federal Securities Laws by Spirit Aviation Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ) between May 28, 2025 and August 29, 2025, have certain options and for certain investors are short and strict deadlines…

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…

Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…

Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
More Releases for Zentalis
Krabbe Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Tr …
Krabbe Disease companies are Jiangsu Hengrui Medicine, AstraZeneca, Y-mAbs Therapeutics, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., MacroGenics, Shanghai Pharmaceuticals Holding, Celgene, Hutchmed, MedImmune LLC, Lee's Pharmaceutical Limited, EMD Serono, Iovance Biotherapeutics, Inc., BioEclipse Therapeutics, BioAtla, Inc., Celgene, Actuate Therapeutics Inc., and others.
According to DelveInsight, the Krabbe Disease pipeline includes over eight leading companies actively engaged in developing more than eight treatment therapies for the condition.
Krabbe Disease Overview:
Krabbe disease…
Osteosarcoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Asses …
Osteosarcoma companies are Isofol Medical, Merck, Eisai Co Ltd, Jiangsu Hengrui Medicine, AstraZeneca, Y-mAbs Therapeutics, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., MacroGenics, Shanghai Pharmaceuticals Holding, Celgene, Hutchmed, MedImmune LLC, Lee's Pharmaceutical Limited, EMD Serono, Iovance Biotherapeutics, Inc., BioEclipse Therapeutics, BioAtla, Inc., Celgene, Actuate Therapeutics Inc., and others.
Osteosarcoma Pipeline constitutes 25+ key companies continuously working towards developing 30+ Osteosarcoma treatment therapies [https://www.delveinsight.com/report-store/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr], analyzes DelveInsight.
Osteosarcoma Overview:
Osteosarcoma, or osteogenic sarcoma, is…
New Horizons in Peritoneal Cancer Market Exploring Future Growth Potential,New D …
A new Report by CoherentMI, titled "Peritoneal Cancer Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032," offers a comprehensive analysis of the industry, which comprises insights on the Peritoneal Cancer market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The Global Peritoneal Cancer Market is estimated to be valued at USD 5.9 Bn in 2024 and is expected to reach USD 15.9…
Peritoneal Cancer Market: Regional Growth, Challenges, and Forecast with CAGR of …
According to a new report published by CoherentMI The Global Peritoneal Cancer Market is estimated to be valued at USD 5.9 Bn in 2024 and is expected to reach USD 15.9 Bn by 2031, growing at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2031.
Most recent Report, named "Peritoneal Cancer Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI offers a complete investigation of…
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuti …
The Osteosarcoma market growth is driven by factors like increase in the prevalence of Osteosarcoma, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Osteosarcoma market report [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Osteosarcoma market size, share, Osteosarcoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Osteosarcoma market…
Revolutionizing Success in the Peritoneal Cancer Market: Latest Trends, Technolo …
The latest release from CoherentMI titled Peritoneal Cancer Market Research Report 2024-2031 (by Product Type, End-User / Application, and Regions / Countries) provides an in-depth assessment of the Peritoneal Cancer including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles, and strategies. Global Peritoneal Cancer Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released BY CoherentMI. The report presents…